Academic Journal
Q1British Journal of Cancer
About British Journal of Cancer
British Journal of Cancer is a scholarly journal published by Springer Nature. SCImago 2025 places it in Q1 with an SJR of 2.803 and an H-index of 290.
Its listed coverage is 1947-2026 and its research categories include Cancer Research (Q1); Oncology (Q1). The 2025 dataset reports 307 documents and 9462 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Global Cancer Incidence and Screening, Cancer, Hypoxia, and Metabolism, Breast Cancer Treatment Studies, Cancer Cells and Metastasis, Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics.
Recent Research Articles
Latest publications matched automatically by ISSN.
Translational modelling challenges receptor‑occupancy‑based dosing of PD‑1 inhibitors like pembrolizumab
Judith D. J. Verdonk, Leila-Sophie Otten, Ghazal Montaseri, Michel M. van den Heuvel et al.
2026-09-05 · DOI: 10.1038/s41416-026-03612-wNeoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus–associated oropharyngeal cancer: a multicentre Phase II trial
Tomoya Yokota, Toyonori Tsuzuki, Tetsuro Onitsuka, Akira Iizuka et al.
2026-09-05 · DOI: 10.1038/s41416-026-03610-yPD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1
Hidekazu Hirano, Yasuhide Yamada, Kengo Nagashima, Nobuyoshi Hiraoka et al.
2026-09-04 · DOI: 10.1038/s41416-026-03607-7Radiomics as a spatial context for treatment decision-making in head and neck cancer
Takeyuki Kono, Ken Kasahara, Ryo Ogawa, Hiroyuki Ozawa et al.
2026-09-03 · DOI: 10.1038/s41416-026-03600-0Triglyceride enhancs NSCLC metastasis via lipid β-oxidation by RhoA-driven cytoskeletal remodeling in ECM-constrained microenvironments
Yingchu Dai, Yufan Ling, Lu Hou, Tianqi Yang et al.
2026-09-03 · DOI: 10.1038/s41416-026-03586-9SLFN11 enhances cisplatin sensitivity in pediatric cancer via activation of stress-response and suppression of survival pathways
Ayesha Jabeen, Dina Awartani, Shimaa Sherif, Eiman I. Ahmed et al.
2026-09-02 · DOI: 10.1038/s41416-026-03571-2Correction: Anti-PDGFRα autoantibody – a novel diagnostic and prognostic marker – may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-κB signaling pathway
Fengqi Chen, Ying Chen, Wenke Sun, Hanke Ma et al.
2026-09-01 · DOI: 10.1038/s41416-026-03576-xWhy early pathology input matters in biologically rich cancer trials
Manas Dave, Maggie Chon U. Cheang, Guy Betts, Tomoko Iwata et al.
2026-09-01 · DOI: 10.1038/s41416-026-03605-9ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids
Alba Zuidema, Levi Nijland, Kyah van Megesen, Mette Marit Vosjan et al.
2026-08-31 · DOI: 10.1038/s41416-026-03581-0Correction: Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of primary care physicians
Elie Rassy, Suzette Delaloge, Yannis Slaouti, Thomas Pudlarz et al.
2026-08-31 · DOI: 10.1038/s41416-026-03597-6Prospective validation of a urine-based proteomics test for predicting clinically significant prostate cancer in biopsy-naïve patients
Ana C. Morillo, Kirubel Nigusu Jobre, Guillermo Lendinez Cano, Ana Blanca-Pedregosa et al.
2026-08-29 · DOI: 10.1038/s41416-026-03602-yOn-treatment core needle biopsy identifies early responders for axillary surgery de-escalation: results from a prospective cohort
Yifan Xie, Siyu Wu, Yan Huang, Ying Zhang et al.
2026-08-27 · DOI: 10.1038/s41416-026-03583-yRisk prediction model for brain metastasis risk among patients diagnosed with primary gastrointestinal cancers
Marc Vincent N. Barcelona, Kaushik Jagannath Kataki, Fadwa Abdel Rahman, Fabio Y. Moraes et al.
2026-08-26 · DOI: 10.1038/s41416-026-03587-8Oligometastatic neuroendocrine tumours: imprecision is not equivalence
Qu Zhang
2026-08-26 · DOI: 10.1038/s41416-026-03604-wThe role of DNA mismatch repair status in oesophagogastric cancer treated with perioperative chemotherapy: evidence from the MRC ST03 and OE05 trials
Panagiotis Ntellas, Tom Lund, Georgina A. Keogh, Manuel Salto-Tellez et al.
2026-08-25 · DOI: 10.1038/s41416-026-03594-9Cancer and Health Inequalities
Donna Wakefield, Clare Bambra
2026-08-24 · DOI: 10.1038/s41416-026-03599-4Dual-oxygen pancreatic cancer organoids recapitulate basal–classical heterogeneity validated by spatial transcriptomics
Koichiro Kumano, Hiromitsu Nakahashi, Osamu Shimomura, Yoshimasa Akashi et al.
2026-08-22 · DOI: 10.1038/s41416-026-03577-wStrategic roadmap for delivery of clinical trials in rare childhood central nervous system (CNS) tumours: a multi-stakeholder consensus
Jenny Adamski, John R. Apps, Sarita Depani, Rebecca M. Hill et al.
2026-08-22 · DOI: 10.1038/s41416-026-03589-6A deep learning-derived risk score model from digital pathology to forecast nivolumab outcomes in gastric carcinoma
Yiyu Hong, Inwoo Hwang, Min-Ji Kim, Yuyeon Kim et al.
2026-08-21 · DOI: 10.1038/s41416-026-03590-zCD39+CD103+CD8+ T cells enhance neoadjuvant chemoimmunotherapy efficacy in head and neck squamous cell carcinoma
Suling Chen, Yupeng Wu, Guangxin Rao, Weihao Tong et al.
2026-08-20 · DOI: 10.1038/s41416-026-03588-7Reviews
Community Reviews
Version History
September 8, 2026 at 12:04 am
September 8, 2026